Cypris Medical
Private Company
Total funding raised: $1.2M
Overview
Cypris Medical is an innovator in the plastic surgery device space, addressing the unmet need for effective, minimally-invasive surgical tools. Its core technology, the Cypris ARC suturing device, utilizes proprietary ARC (Accurate Repeatable Capture) geometry and Negative Pressure Suturing (NPS) to enable precise tissue capture and suture delivery through small access points. The company is initially targeting facial and neck contouring procedures, with a pipeline exploring applications in breast reconstruction, body contouring, and general surgery. Led by a team with deep medical device and plastic surgery expertise, Cypris aims to commercialize technology designed by plastic surgeons for plastic surgeons.
Technology Platform
The Cypris ARC platform is a handheld surgical suturing system featuring proprietary ARC (Accurate Repeatable Capture) geometry for precise tissue purchase and Negative Pressure Suturing (NPS) for tissue capture via vacuum, enabling minimally-invasive precision suturing.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Cypris ARC competes in the broad aesthetic surgery device market against large players like Allergan Aesthetics (AbbVie), Mentor (J&J), and numerous suture companies. Its direct competition includes other minimally-invasive lifting/suturing devices and techniques, but it claims uniqueness as the first device of its kind for precise, minimal-access suture delivery in plastic surgery.